The fabrication process of FoxO3-NETT is demonstrated in
Fig. 2A. The “Cargo” (Cas9-sgFoxO3), which regulates autophagic activation, was designed and fabricated by a CRISPR/Cas9-based FoxO3-targeted gene-editing tool (Figs. S1 and S2). To ensure specific delivery of the “Cargo” (Cas9-sgFoxO3) to OA chondrocytes for ameliorating mitochondrial dysfunction, a chondrocyte-targeting nanoengineered “truck” (NETT) loaded with “Cargo” was developed. To achieve this, liposomes containing SgFoxO3 plasmids (Lip) were fused to exosomes containing Cas9 protein (TExo, Figs. S1 and S2) to target chondrocytes, which is referred as FoxO3-NETT. For comparison, NETT was fabricated as a control using the same process, but without loading the FoxO3 gene-editing tool. TEM images confirmed the nano-sized spherical vesicle morphology of Lip, TExo, NETT, and FoxO3-NETT (
Fig. 2B). As illustrated in
Fig. 2C, the average sizes of Lip, TExo, NETT, and FoxO3-NETT were 125.39 nm, 139.82 nm, 153.69 nm, and 163.44 nm, respectively. The surface charges of Lip, TExo, NETT, and FoxO3-NETT were further assessed by DLS. Despite the negative charge of –24.78 ± 2.82 mV in TExo and a positive charge of 31.10 ± 2.20 mV in Lip, there was a slight positive surface zeta potential for NETT as well as FoxO3-NETT (
Fig. 2D). The mild positive charge on NETT and FoxO3-NETT particles may help them target more efficiently inside joints. This is attributed to the subtle positive charge on their surfaces, which allows them to adhere better to negatively charged surfaces of chondrocytes and glycosaminoglycan chains within cartilage tissue
40. The stability of the delivery vesicle is crucial for OA therapy. It can be seen from
Fig. 2E that the particle size of both NETT and FoxO3-NETT was consistently constant after 30 days, whereas TExo gradually increased after Day 6. Additionally, RT-PCR testing was employed to assess the loading efficiency and effectiveness of the CRISPR/Cas9-based FoxO3-targeted gene-editing tool (Cas9-sg FoxO3) in FoxO3-NETT, confirming successful loading of Cas9-sg FoxO3 in FoxO3-NETT (
Fig. 2F and Supporting Information Fig. S4). Furthermore,
Fig. 2G demonstrated that FoxO3-NETT promotes
Foxo3 gene expression in chondrocytes by delivering the gene editor Cas9-sgFoxO3. To verify the enhanced uptake efficiency of FoxO3-NETT in chondrocytes
in vitro, DIO-labeled natural EXO, TExo, or FoxO3-NETT were incubated with chondrocytes for 4 h. The FoxO3-NETT group showed higher green fluorescence signals (blue nucleus) than either EXO or TExo groups, suggesting more FoxO3-NETT were taken up by chondrocytes (
Fig. 2H (i)). The enhanced uptake of FoxO3-NETT within chondrocytes is attributed to the weak positive surface charge, which is more favorable to bind the negatively charged chondrocyte surface
via electrostatic interaction, while the strong negative charge of TExo results in the electrostatic repulsion between the nanoparticles and cells
41. Collectively, these results confirm the enhanced chondrocyte-targeting of FoxO3-NETT. Semi-quantitative analysis of mean optical density (
Fig. 2H(ii)) further consolidated previous conclusions. Based on these findings, FoxO3-NETT is proven to be effective in chondrocyte-specific targeting
in vitro.